NR 546 MIDTERM EXAM -
NEUROBIOLOGY AND
PSYCHOPHARMACOLOGY
ESSENTIALS QUESTIONS WITH
CORRECT ANSWERS (LATEST 2026 /
2027), (A+ GUARANTEE).
1. Which of the following best describes the action of a ‘partial agonist’ at a neurotransmitter
receptor?
A. It blocks the receptor entirely, preventing any biological response.
B. It acts as a stabilizer, providing more activity than an antagonist but less than a full
agonist.
C. It increases the affinity of the natural neurotransmitter for the receptor site.
D. It activates the receptor to a submaximal level regardless of the concentration of the full
agonist.
Answer: B
Conceptual Explanation: Partial agonists are often called ‘tuners’ or stabilizers. In the
absence of a full agonist, they exert partial agonistic activity; in the presence of a full
agonist, they act as functional antagonists by competing for the same site but producing a
lesser effect.
,2. A patient is a known ‘ultra-rapid metabolizer’ for the CYP450 2D6 enzyme. What is the
clinical implication when prescribing a drug that is a substrate of 2D6?
A. The patient will likely require a higher dose to achieve therapeutic levels.
B. The patient will likely require a lower dose to avoid toxicity.
C. The drug will be absorbed more slowly from the GI tract.
D. The drug will have a significantly longer half-life.
Answer: A
Conceptual Explanation: Ultra-rapid metabolizers break down medications faster than
the average person, leading to lower plasma concentrations and often requiring higher
doses to reach the therapeutic window.
3. Which dopamine pathway is primarily associated with the ‘negative symptoms’ of
schizophrenia, such as cognitive impairment and affective flattening?
A. Mesolimbic pathway
B. Mesocortical pathway
C. Nigrostriatal pathway
D. Tuberoinfundibular pathway
Answer: B
, Conceptual Explanation: Hypofunction or low dopamine in the mesocortical pathway
(specifically the dorsolateral prefrontal cortex) is linked to negative symptoms and
cognitive dysfunction.
4. In the process of signal transduction, what is the role of a ‘second messenger’ like cyclic
adenosine monophosphate (cAMP)?
A. It binds directly to the presynaptic transporter to inhibit reuptake.
B. It serves as a structural protein to maintain the shape of the neuron.
C. It acts as the primary neurotransmitter released into the synaptic cleft.
D. It converts extracellular signals into intracellular responses by activating protein
kinases.
Answer: D
Conceptual Explanation: Second messengers transmit the signal from the cell surface
(where the neurotransmitter binds) to the interior of the cell, often triggering
phosphorylation via protein kinases to change gene expression or ion channel state.
5. Approximately how many half-lives does it take for a medication to reach ‘steady state’ in
the plasma?
A. 1 to 2 half-lives
B. 24 hours, regardless of the drug
C. 10 to 12 half-lives
NEUROBIOLOGY AND
PSYCHOPHARMACOLOGY
ESSENTIALS QUESTIONS WITH
CORRECT ANSWERS (LATEST 2026 /
2027), (A+ GUARANTEE).
1. Which of the following best describes the action of a ‘partial agonist’ at a neurotransmitter
receptor?
A. It blocks the receptor entirely, preventing any biological response.
B. It acts as a stabilizer, providing more activity than an antagonist but less than a full
agonist.
C. It increases the affinity of the natural neurotransmitter for the receptor site.
D. It activates the receptor to a submaximal level regardless of the concentration of the full
agonist.
Answer: B
Conceptual Explanation: Partial agonists are often called ‘tuners’ or stabilizers. In the
absence of a full agonist, they exert partial agonistic activity; in the presence of a full
agonist, they act as functional antagonists by competing for the same site but producing a
lesser effect.
,2. A patient is a known ‘ultra-rapid metabolizer’ for the CYP450 2D6 enzyme. What is the
clinical implication when prescribing a drug that is a substrate of 2D6?
A. The patient will likely require a higher dose to achieve therapeutic levels.
B. The patient will likely require a lower dose to avoid toxicity.
C. The drug will be absorbed more slowly from the GI tract.
D. The drug will have a significantly longer half-life.
Answer: A
Conceptual Explanation: Ultra-rapid metabolizers break down medications faster than
the average person, leading to lower plasma concentrations and often requiring higher
doses to reach the therapeutic window.
3. Which dopamine pathway is primarily associated with the ‘negative symptoms’ of
schizophrenia, such as cognitive impairment and affective flattening?
A. Mesolimbic pathway
B. Mesocortical pathway
C. Nigrostriatal pathway
D. Tuberoinfundibular pathway
Answer: B
, Conceptual Explanation: Hypofunction or low dopamine in the mesocortical pathway
(specifically the dorsolateral prefrontal cortex) is linked to negative symptoms and
cognitive dysfunction.
4. In the process of signal transduction, what is the role of a ‘second messenger’ like cyclic
adenosine monophosphate (cAMP)?
A. It binds directly to the presynaptic transporter to inhibit reuptake.
B. It serves as a structural protein to maintain the shape of the neuron.
C. It acts as the primary neurotransmitter released into the synaptic cleft.
D. It converts extracellular signals into intracellular responses by activating protein
kinases.
Answer: D
Conceptual Explanation: Second messengers transmit the signal from the cell surface
(where the neurotransmitter binds) to the interior of the cell, often triggering
phosphorylation via protein kinases to change gene expression or ion channel state.
5. Approximately how many half-lives does it take for a medication to reach ‘steady state’ in
the plasma?
A. 1 to 2 half-lives
B. 24 hours, regardless of the drug
C. 10 to 12 half-lives
